A Retrospective Study of Biochemotherapy for Metastatic Melanoma: The Importance of Dose Intensity
| Autor: | David R. Minor, William B. Harvey, Susan R. Denny, Mohammed Kashani-Sabet, Michael T. Madland |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Oncology Cancer Research Pathology medicine.medical_treatment Antineoplastic Combined Chemotherapy Protocols Medicine Neoplasm Metastasis Melanoma Clinical Trials as Topic General Medicine Middle Aged Combined Modality Therapy Recombinant Proteins Vinblastine Dacarbazine Treatment Outcome Female medicine.drug Adult medicine.medical_specialty Maximum Tolerated Dose Alpha interferon Antineoplastic Agents Interferon alpha-2 Disease-Free Survival Internal medicine Temozolomide Humans Immunologic Factors Radiology Nuclear Medicine and imaging Antineoplastic Agents Alkylating Aged Retrospective Studies Pharmacology Cisplatin Chemotherapy business.industry Interferon-alpha Retrospective cohort study medicine.disease Antineoplastic Agents Phytogenic Interleukin-2 business |
| Zdroj: | Cancer Biotherapy and Radiopharmaceuticals. 20:479-486 |
| ISSN: | 1557-8852 1084-9785 |
| DOI: | 10.1089/cbr.2005.20.479 |
| Popis: | The utility of biochemotherapy for metastatic melanoma remains controversial. Dose intensity has been recognized as an important determinant of response and survival in the chemotherapy of several malignancies but has not been studied in biochemotherapy. In this retrospective study, we described the relationship between achieved dose intensity and the response rate of inpatient decrescendo biochemotherapy at our center.A study of 38 consecutive patients with metastatic melanoma was undertaken. The planned doses were dacarbazine 800 mg/m(2) on day 1 or temozolomide 150 mg/m(2) on days 1-4, cisplatin 20 mg/m(2) on days 1-4, vinblastine 1.5 mg/m(2) on days 1-4, interferon-alpha-2b (Schering) 5 million IU (MIU)/m(2) on days 1-5, and interleukin-2 36 MIU on day 1, 18 MIU on day 2, and 9 MIU on days 3 and 4.Of 38 patients that received a total of 204 cycles of therapy, 8 (21%) complete responses and 14 (37%) partial responses were observed for an objective response rate of 58%. Median survival was 19.6 months. Achieved dose intensity was high with patients receiving 98.7% interleukin- 2, 87.1% interferon, 90.7% dacarbazine (DTIC), 94% temozolomide, 87.2% cisplatin, and 89.7% vinblastine.Six cycles of inpatient decrescendo biochemotherapy can be given with high-dose intensity and acceptable toxicity. High response rates with biochemotherapy for melanoma may correlate with dose intensity, dose density, and the number of cycles given on time. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|